WANBURY
Back to Income Statement
|
WANBURY Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹600 Cr | ₹578 Cr | ₹500 Cr | ₹511 Cr | ₹393 Cr |
What is the latest Revenue of WANBURY ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹600 Cr |
| Mar2024 | ₹578 Cr |
| Mar2023 | ₹500 Cr |
| Mar2022 | ₹511 Cr |
| Mar2021 | ₹393 Cr |
How is Revenue of WANBURY Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹600 Cr | 3.77 | |
| Mar2024 | ₹578 Cr | 15.63 | |
| Mar2023 | ₹500 Cr | -2.26 | |
| Mar2022 | ₹511 Cr | 30.23 | |
| Mar2021 | ₹393 Cr | - | |
Compare Revenue of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹928.2 Cr | 16.1% | 3.2% | 5.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹406,243.0 Cr | -1.4% | -7.2% | 0.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,179.0 Cr | 5.7% | 0.3% | 14.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹140,670.0 Cr | 1.5% | -6.5% | 28.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,932.0 Cr | 0.7% | -7.4% | 9.9% | Stock Analytics | |
| CIPLA | ₹99,417.9 Cr | 0.5% | -7.1% | -14.4% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | 16.1% |
3.2% |
5.7% |
| SENSEX | 0.6% |
1.5% |
6.6% |
You may also like the below Video Courses